DeepMed Research

Takeda Pharmaceutical Company Ltd

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study of Surgical Interventions in Fistulizing Conditions

Active, not recruiting

Conditions: Complex Cryptoglandular Fistula
Complex Perianal Fistula
Crohns Disease
Fistula
Rectovaginal Fistula

First Posted Date: 2021-06-25

Last Posted Date: 2025-03-19

Lead Sponsor: Takeda

Target Recruit Count: 750

Registration Number: NCT04940611

Locations: 🇫🇷
CHU de Rouen - Hopital Charles Nicolle, Rouen Cedex, Seine Maritime, France
🇨🇿
Fakultni nemocnice Olomouc, Olomouc, Czechia
🇬🇧
Broomfield Hospital, Chelmsford, Essex, United Kingdom

and more 38 locations

A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

Phase 3

Completed

Conditions: Lennox Gastaut Syndrome (LGS)

Interventions: Drug: Soticlestat
Drug: Placebo

First Posted Date: 2021-06-24

Last Posted Date: 2024-08-21

Lead Sponsor: Takeda

Target Recruit Count: 270

Registration Number: NCT04938427

Locations: 🇺🇸
St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇭🇺
Pecsi Tudomanyegyetem, Pecs, Baranya, Hungary

and more 95 locations

Assessment of Updated Educational Materials for Instanyl®

Completed

Conditions: Cancer Pain
Pain

First Posted Date: 2021-06-24

Last Posted Date: 2023-08-01

Lead Sponsor: Takeda

Target Recruit Count: 536

Registration Number: NCT04938440

Locations: 🇺🇸
Central Contact, Cambridge, Massachusetts, United States

Survey of the Moderna COVID-19 Vaccine in People at High-Risk of Developing Severe COVID-19 Symptoms

Withdrawn

Conditions: Coronavirus Disease (COVID-19)

Interventions: Biological: COVID-19 Vaccine

First Posted Date: 2021-05-19

Last Posted Date: 2022-07-28

Lead Sponsor: Takeda

Registration Number: NCT04892888

Locations: 🇯🇵
Takeda Selected Site, Tokyo, Japan

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in Real-World Practice

Completed

Conditions: Crohns Disease
Colitis, Ulcerative
Inflammatory Bowel Diseases

First Posted Date: 2021-05-18

Last Posted Date: 2024-10-16

Lead Sponsor: Takeda

Target Recruit Count: 99

Registration Number: NCT04890262

Locations: 🇦🇹
Medizinische Universitat Graz, Graz, Austria
🇦🇹
Medizinische Universitat Innsbruck, Innsbruck, Austria
🇦🇹
Krankenhaus der Barmherzigen Bruder, St. Veit/Glan, Austria

and more 4 locations

A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC)

Completed

Conditions: Anaplastic Lymphoma Kinase
Carcinoma, Non-Small-Cell Lung

Interventions: Other: No Intervention

First Posted Date: 2021-05-14

Last Posted Date: 2023-04-18

Lead Sponsor: Takeda

Target Recruit Count: 39

Registration Number: NCT04887519

Locations: 🇦🇷
IC Projects, Buenos Aires, Argentina

A Study on Administration Choices of Vedolizumab and Outcomes for Adults With Inflammatory Bowel Disease (IBD) (VARIETY - CROATIA AND SLOVENIA)

Completed

Conditions: Inflammatory Bowel Diseases
Crohns Disease
Colitis, Ulcerative

First Posted Date: 2021-05-13

Last Posted Date: 2024-04-16

Lead Sponsor: Takeda

Target Recruit Count: 120

Registration Number: NCT04885920

Locations: 🇭🇷
Klinicki bolnicki centar Osijek (University medical centre Osijek), Osijek, Croatia
🇭🇷
Klinicki bolnicki centar Rijeka (University medical centre Rijeka), Rijeka, Croatia
🇸🇮
Univerzitetni klinicni center Ljubljana (University medical Centre Ljubljana), Ljubljana, Slovenia

and more 5 locations

A Study With Teduglutide (Revestive®) in Adults With Short Bowl Syndrome

Completed

Conditions: Short Bowel Syndrome

First Posted Date: 2021-05-12

Last Posted Date: 2023-08-31

Lead Sponsor: Takeda

Target Recruit Count: 65

Registration Number: NCT04883606

Locations: 🇪🇸
Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain

A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers

Phase 1

Completed

Conditions: Squamous Cell Carcinoma of Head and Neck
Carcinoma, Non-Small-Cell Lung
Triple Negative Breast Neoplasms

Interventions: Drug: Pembrolizumab
Drug: TAK-676
Radiation: Image-guided radiation therapy

First Posted Date: 2021-05-10

Last Posted Date: 2024-06-11

Lead Sponsor: Takeda

Target Recruit Count: 34

Registration Number: NCT04879849

Locations: 🇺🇸
Cedars Sinai Medical Center, Duarte, California, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States

and more 2 locations

A Study of Teduglutide (Revestive®) in Children, Teenagers and Adults With Short Bowel Disease

Completed

Conditions: Short Bowel Syndrome

First Posted Date: 2021-05-07

Last Posted Date: 2023-07-19

Lead Sponsor: Takeda

Target Recruit Count: 45

Registration Number: NCT04877431

Locations: 🇦🇷
IC Projects, Buenos Aires, Argentina

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy